Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results

BEIJING, Nov. 10  /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Monday, November 16, 2009 at 9:00 a.m. ET to review the Company's third quarter financial results for the period ended September 30, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international).  A replay of the call will be available from 12:00 p.m. ET on November 16, 2009 to November 30, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 337401.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com/ . A webcast replay can be accessed on the corporate website beginning November 16, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products, including Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza), Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), and PANFLU.1(TM), Sinovac's H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

  For more information, please contact:

   Helen G. Yang
   Sinovac Biotech Ltd.
   Tel:   [phone] x871
   Fax:   [phone]
   Email: 

  Media:
   Janine McCargo
   The Ruth Group
   Tel:   [phone]
   Email: 

  Investors:
   Amy Glynn/Stephanie Carrington
   The Ruth Group
   Tel:   [phone]
   Email: 

DATASOURCE: Sinovac Biotech Ltd.



CONTACT:  Helen G. Yang of Sinovac Biotech Ltd., [phone] x871,

fax, [phone], or ; Media: Janine McCargo of The Ruth

Group, [phone], or ; Investors: Amy Glynn,

Stephanie Carrington of The Ruth Group, [phone]/7017, or

,  



Web site:  http://www.sinovac.com/ 

Copyright